Finland's Biotie Therapies Renegotiates Nalmefene Deal And Receives €30 Million Funding Lifeline
This article was originally published in The Pink Sheet Daily
Executive Summary
With the end of its cash runway on the horizon, Finland’s Biotie Therapies has received an equity investment of €10 million from Lundbeck and €20 million from institutional investors, after renegotiating the ex-Europe part of its worldwide nalmefene licensing pact.
You may also be interested in...
NICE Nod For Selincro May Give Lundbeck Much Needed Revenue Boost
NICE's positive recommendation for Lundbeck's Selincro for alcohol dependence should give the Danish biotech a revenue boost and help offset expiry of its Lexapro/Cipralex patent.
UCB Exercises Tozadenant Option But Asks Biotie To Move It To Phase III
Biotie Therapies gets $20 million as UCB exercises its option on the investigational Parkinson's disease therapy tozadenant and asks the Finnish biotech to continue its clinical development of the product into Phase III.
EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum
Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).